Europe Biopsy Devices Market Analysis, Size, and Share by 2027

The Europe biopsy devices marketis expected to reach US$ 1,090.67million by 2027 from US$ 700.01million in 2019; it is estimated to grow at a CAGR of 5.8% from 2020 to 2027.

The key factors driving the growth of biopsy devices are the increasing prevalence of cancer and government support and initiatives. However, limitations associated to biopsy devicesis the major factor hindering the market growth in Europe.

A biopsy is a medical examination generally implemented by surgeons, interventional radiologists, or interventional cardiologists to extract sample cells or tissues for the identification and diagnosis of a disease. The tissue is further examined microscopically by pathologists, or is tested through chemical procedures. Biopsies are most commonly performed to identify cancerous and inflammatory conditions.

Biopsy refers to a diagnostic test that helps identify various types of cancer and noncancerous abnormalities in a human body. The increasing prevalence of cancer is likely to augment the growth of the biopsy devices market in the coming years. As per the Cancer Research, UK, ~367,000 new cancer cases are registered in the UK every year, i.e., ~1,000 per day (2015–2017). Every two minutes someone in the UK is diagnosed with cancer. Additionally, rapidly changing lifestyle and growing alcohol and tobacco product consumptiontrend are among the prominent factors resulting in the increasing incidence of cancer in Europe.

Qiagen and F.Hoffmann La-Roche Ltd are among the major companies manufacturing biopsy devices and accessories used in the diagnosis of cancer and other diseases. Therefore, the increasing prevalence of cancer is expected to drive the growth of the Europe biopsy devices market during the forecast period.

The European Society for Medical Oncology (ESMO), a leading professional organization for medical oncology, continues to help oncology professionals deliver optimal care to their cancer patients amid the COVID-19 pandemic. The impact of this pandemic on cancer patients is high in terms of anxiety, fear, and psychological distress. However, shutdown of businesses and other measures imposed in different countries are delaying the supply of diagnostics kits and assays. Many companies from the biopsy devices market have redirected their focus on the development of the COVID-19 test. For instance, Qiagen is looking to steeply ramp up its global production of the RNA test reagents used to perform specific COVID-19 diagnostics.

Rest of Europe Biopsy Devices Market,Revenue and Forecast to 2027 (US$ Million)

EUROPE BIOPSY DEVICES MARKET SEGMENTATION

By Product

• Needle-Based Biopsy
• Core Biopsy Devices
• Aspiration Biopsy Needles
• Vacuum-Assisted Biopsy (VAB) Devices
• Localization Wires
• Procedure Trays
• Others

By Application

• Lung Biopsy
• Kidney Biopsy
• Liver Biopsy
• Breast Biopsy
• Others

By Technology

• CT-Scan
• Ultrasound-Guided Biopsy
• Stereotactic-Guided Biopsy
• MRI-Guided Biopsy
• Others

By Country

• Germany
• France
• UK
• Italy
• Spain
• Sweden
• Norway
• Denmark

Company Profiles

• B. Braun Melsungen AG
• Medtronic
• Cardinal Health Inc.
• Danaher
• Hologic, Inc.

Europe Biopsy Devices Report Scope